SCHEMBL6475302

SCHEMBL6475302

CN(C)CCCOc1ccc(CCc2ccc(Nc3ccccc3C(=O)O)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
RECQL P46063 1/20 0.54
BLM P54132 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
HRH3 Q9Y5N1 2/20 0.51
SIRT2 Q8IXJ6 3/20 0.51
CACNA1B Q00975 3/20 0.51
ALDH1A1 P00352 2/20 0.49
MAPT P10636 1/20 0.49
TEAD4 Q15561 1/20 0.49
CACNA1H O95180 1/20 0.48
KDM4E B2RXH2 1/20 0.47
LSS P48449 1/20 0.47
LTA4H P09960 2/20 0.47
BCL2 P10415 1/20 0.46
FABP4 P15090 1/20 0.46
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482582 0.85 PLK1 (0.64) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475460 0.81 SIRT2 (0.73) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475772 0.80 MEN1 (0.76) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475426 0.80 MEN1 (0.64) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6482855 0.79 SIRT2 (0.77) MEN1KMT2ARECQLBLMTDP1
SCHEMBL4250051 0.79 PLK1 (0.70) MEN1KMT2AALDH1A1MAPTTEAD4
SCHEMBL11264560 0.78 HRH3 (0.77) HRH3CACNA1BALDH1A1KDM4ELSS
SCHEMBL10385662 0.77 NPC1 (0.67) MEN1KMT2ASIRT2ALDH1A1MAPT
SCHEMBL6476391 0.76 MEN1 (0.57) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6485780 0.76 MEN1 (0.60) MEN1KMT2ARECQLBLMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885KMT2A 4729/4885RECQL 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.